Early Detection of Five Common Cancers Using the ctDNA Analysing Test (NCT05227261) | Clinical Trial Compass
CompletedNot Applicable
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
Vietnam9,057 participantsStarted 2022-04-10
Plain-language summary
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
Primary objective: To evaluate the performance characteristics of the blood ctDNA test in early detecting cancers.
Secondary objectives:
* To evaluate the performance characteristics of the test in determining the origin of tumour, as compared to the findings of the imaging diagnostic tests.
* To determine the risk of cancers development in the high-risk population, as compared to that in the moderate-risk group.
Who can participate
Age range
40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 40 or above at enrolment
* Neither clinical suspicion of cancer nor history of confirmed cancer has been reported
* Agree to be contacted at 6 months and 12 months following enrolment to collect information about general health status and progress of cancer (if possible)
* Provide written informed consent
Exclusion Criteria: If a potential participant has any one of the following criteria, he/she will not be able to be enrolled in the study:
* History of cancer (cancer has either been confirmed or been treated within the past 3 years)
* History of blood transfusion or bone marrow transplantation within the past 3 years
* Does not agree to participate in study
* The subject has clinical manifestations of pregnant.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Positive predictive value, Negative predictive value of the blood ctDNA test in early detecting cancers
Timeframe: 12 months following enrolment
2
Sensitivity and specificity of the test in early detecting cancers